Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy
Phase 2
140
about 7 years
30+
Male only
1 site in NE
About this study
This trial is testing whether a treatment with abiraterone and prednisone, plus standard hormone therapy, is better than standard hormone therapy alone for prostate cancer patients whose lymph nodes show signs of the disease using a special imaging test. The goal is to see if this new treatment leads to longer survival without the cancer coming back compared to the usual treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Hormone therapy
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
hormone therapy, abiraterone, prednisone
oral
Secondary: Evaluate 5-year overall survival, Evaluate and compare patient-reported symptom outcomes in both arms from 3 months to 2 years post-ADT. (FACT-P), Evaluate and compare patient-reported symptom outcomes in both arms from 3 months to 2 years post-ADT. (IPSS), Evaluate local progression-free survival (i.e., failure-free survival excluding biochemical failure)., Evaluate locoregional progression-free survival (i.e., failure-free survival excluding biochemical failure)., Toxicity in both arms from 3 months to 2 years post-ADT.
radiation
Oncology